Brief: Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma

Castle Biosciences

05/09/2024 12:22

Sept 5 (Reuters) - Castle Biosciences Inc  CSTL.O :
    * STUDY CONFIRMS THE ABILITY OF CASTLE BIOSCIENCES'
DECISIONDX®-SCC TEST TO PREDICT LIKELIHOOD OF BENEFIT FROM
ADJUVANT RADIATION THERAPY IN PATIENTS WITH HIGH-RISK CUTANEOUS
SQUAMOUS CELL CARCINOMA

Source text for Eikon:  ID:nBw42nXyPa 
Further company coverage:  CSTL.O 

 ((Reuters.Briefs@thomsonreuters.com;))